Starlix

Quick links to important sections

Starlix

Selected form

Method of action: Drugs Used In Diabets

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Starlix

Property Description
Active Ingredient Nateglinide
Form Tablets
Pharmacological Class Meglitinide (Glinide)
General Purpose Glycemic control (Post-meal blood sugar management)
Origin Synthetic amino acid derivative

Nateglinide: Defining the Starlix Drug Type

Starlix is a prescription-only oral antidiabetic agent used for the management of Type 2 diabetes mellitus. Its active compound is nateglinide, which is classified as a meglitinide pharmacological agent. Meglitinides, often referred to as glinides, are structurally distinct from older sulfonylurea agents, yet they share the function of promoting insulin release. Nateglinide is recognized for its unique, highly rapid onset of action and very short duration of action compared to these older classes, a key feature that dictates its usage timing.

Composition, Form, and Origin of Starlix

The active ingredient, nateglinide, is chemically characterized as a synthetic amino acid derivative—a compound designed to provide a specific therapeutic effect. Starlix is supplied as a single active ingredient product in the form of oral tablets. Nateglinide is an established tool for managing type 2 diabetes by addressing the early-phase insulin deficiency. The formulation is specifically designed to be taken immediately before eating, leveraging its rapid absorption to ensure the medication's action coincides precisely with the digestive process.

What is the General Purpose of Starlix?

The general purpose of Starlix is to provide targeted glycemic control by directly counteracting postprandial hyperglycemia—the rapid and excessive spike in blood sugar that follows food consumption. As a short-acting insulin secretagogue, its function is to prompt the pancreatic beta-cells to release a quick, temporary surge of insulin precisely when the body is processing meal-derived glucose. This distinct physiological effect aims to address the characteristic early-phase insulin deficiency observed in many patients with Type 2 diabetes mellitus, thus focusing on normalizing blood glucose levels at mealtime.

What side effects are possible with Starlix?

Possible Side Effects and Safety Information

The safety profile of Nateglinide (Starlix) is characterized by its pharmacological class, focusing on officially documented adverse reactions and strict use limitations defined by regulatory authorities.


Adverse Reaction Classification

Side effects are formally classified based on the frequency observed in clinical data. The most characteristic and common adverse reaction is hypoglycemia (low blood sugar). Other common effects include upper respiratory tract infection, back pain, dizziness, and various gastrointestinal disorders such as diarrhea, abdominal pain, dyspepsia, and nausea.

Reactions classified as uncommon include vomiting. Rare documented effects include hypersensitivity reactions (e.g., rash, urticaria) and elevations in liver enzymes. Very rare serious post-marketing events, such as cholestatic hepatitis and Erythema multiforme, have also been reported.


Serious Reactions and Use Restrictions

Official labeling documents episodes of severe hypoglycemia, which is a clinically significant adverse reaction. The safety profile establishes several absolute constraints, defining conditions where the medication is strictly contraindicated.

Contraindicated conditions include severe hepatic impairment, Type 1 diabetes mellitus, and diabetic ketoacidosis. Furthermore, the use of Nateglinide is generally not recommended for the pediatric population (under 18 years) due to limited safety data. The potential for hypoglycemia can also affect a patient’s ability to perform tasks requiring concentration, such as driving.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory profile for Starlix (nateglinide) overdose centers on the risk of hypoglycemia (excessively low blood sugar), the drug’s primary physiological effect.

Manifestations Severe Outcomes and Management
Documented Symptoms are consistent with hypoglycemia, including sweating, trembling, dizziness, palpitations, nausea, and weakness. Signs such as confusion, blurred vision, or slurred speech are also noted. Overdose can result in severe hypoglycemia, defined by extremely low plasma glucose concentrations, which is classified as life-threatening and carries a risk of death. Potential severe complications include seizures (convulsions).
Population Notes: Patients with impaired hepatic function may be at increased risk of overdose effects due to greater systemic exposure. Supportive Care: Management is symptomatic and supportive. Regulatory information states that dialysis is not an efficient means of removing the drug due to its high protein binding.

Emergency Action: When to Seek Immediate Medical Help

Regulatory guidance mandates that patients or caregivers seek immediate emergency medical attention upon suspected overdose. Urgent care is required for any manifestation of severe hypoglycemia or associated complications such as seizures.

Therapeutic Uses of Starlix

Starlix: Main Uses and Benefits

Starlix is a prescription medication used to assist with the management of high blood sugar levels in adults diagnosed with Type 2 Diabetes Mellitus. Its therapeutic role is to complement a structured plan of diet modifications and regular exercise to help support blood sugar management. This approach may help patients achieve and sustain more stable glycemic levels.

This medication is typically considered for use in clinical situations where adults require assistance in managing blood glucose, especially levels that rise following meals. It may be prescribed as a stand-alone therapy or as part of a combination regimen with other appropriate medications for Type 2 diabetes.


Quick Fact: Relief for High Blood Sugar (Hyperglycemia)


Eligibility and Restrictions for Use

Starlix (nateglinide) is officially approved for use in adults to help manage Type 2 diabetes mellitus. Eligibility for the drug is strictly defined by regulatory documents, which outline several absolute exclusions and limitations.

Populations Who Must Not Use Starlix (Contraindications)

The medicine is contraindicated (must not be used) in patients with the following conditions or characteristics:

  • Hypersensitivity or allergy to nateglinide or any of the inactive ingredients.
  • Type 1 diabetes mellitus or diabetic ketoacidosis (DKA).
  • Severe hepatic impairment (severe liver disease), as clinical studies have not been conducted in this group.
  • Pregnancy and breastfeeding (use is not recommended, and in some regions, contraindicated).

Populations Requiring Special Caution

Use is generally not recommended or requires caution in certain specific groups due to an increased potential for hypoglycemia or a lack of clinical data:

  • Children and Adolescents (under 18 years): Safety and efficacy have not been established, and use is not recommended.
  • Moderate Hepatic Impairment: Requires caution and careful monitoring.
  • Severe Renal Impairment: Patients may be more susceptible to the glucose-lowering effect.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Starlix (nateglinide) has officially documented interaction patterns that are classified based on their effect on the drug's concentration (pharmacokinetic) or its effect on blood sugar (pharmacodynamic). These interaction patterns require consideration based on official regulatory labeling.

Pharmacokinetic Interactions

Co-administration with potent CYP2C9 inhibitors, such as fluconazole or gemfibrozil, is documented to result in a modest increase in nateglinide's systemic exposure (AUC). Conversely, agents that act as CYP enzyme inducers, including rifampin, phenytoin, and the herbal product St. John's Wort, may reduce nateglinide concentrations, potentially leading to a reduced overall hypoglycemic effect.

Pharmacodynamic Interactions

The blood sugar-lowering effect may be enhanced when nateglinide is combined with other agents, including non-selective beta-blockers, NSAIs, or MAOIs. Conversely, the effect may be reduced by substances such as diuretics and corticosteroids.

Interaction-Related Restrictions

The medicine is contraindicated in patients with severe hepatic impairment due to significantly altered drug clearance and heightened interaction risk. The use of nateglinide is restricted with alcohol ingestion due to a documented increase in the risk of hypoglycemia. Caution is also specifically noted for individuals identified as CYP2C9 poor metabolizers due to the potential for higher plasma exposure.

Mechanism of Action

Molecular Mechanism: K ATP Channel Blockade

Nateglinide initiates its action by targeting the Sulfonylurea Receptor 1 (SUR1) subunit of the ATP-sensitive Potassium Channel ( K ATP Channel) located on the pancreatic beta-cell surface. The drug acts as an inhibitor, causing the channel to close and preventing the efflux of potassium ( K^+) ions . This initial molecular step alters the cell’s electrical gradient, which is the necessary condition to initiate the insulin release cascade.


Mechanistic Cascade: Calcium Influx and Pulsatile Secretion

The electrical change resulting from K ATP channel closure is cellular membrane depolarization, which immediately triggers the opening of voltage-gated Calcium ( Ca^2+) channels. The rapid influx of Ca^2+ acts as the final intracellular messenger, stimulating the exocytosis of stored insulin granules. This sequence creates a brief, concentrated pulse of insulin secretion, an effect that is characteristic of the physiological early-phase insulin secretion.


⏱️ Kinetic Precision and Glucose Dependence

A defining feature of the Nateglinide mechanism is its rapid association and dissociation kinetics (fast on/fast off) at the SUR1 receptor, resulting in an insulin pulse that is transient and short-lived. This action is also inherently glucose-dependent, meaning the magnitude of insulin release is significantly enhanced when ambient glucose levels are elevated. This dual kinetic and chemical constraint contributes to a transient and glucose-appropriate physiological response.

Dosage and Administration Information

How to Use Starlix

Starlix (nateglinide) is an oral antidiabetic agent prescribed as a film-coated tablet. The official usage pattern is structured by the drug's rapid onset and short duration of action, requiring precise coordination with food consumption to manage post-meal blood sugar levels.


Dosing and Administration

The medicine is prescribed for administration three times daily (tid), corresponding to the three main meals. The standard adult regimen involves taking 120 mg tid. A lower starting dose of 60 mg tid may be utilized when initiating therapy for patients closer to their blood sugar management goals. The primary instruction for use is the required time-relationship to meals: each dose must be taken 1 to 30 minutes before the meal begins. This constraint ensures the drug's effect coincides directly with glucose absorption.


Procedural Constraints and Specific Populations

The official labeling provides a clear instruction regarding meal-dependency: if a meal is skipped, the scheduled dose of the medication is also skipped. This rule is a critical functional constraint of the treatment regimen. Regarding specific populations, no dose adjustment is generally necessary for older adults or in patients with mild-to-severe renal impairment. However, administration is not recommended in the pediatric population, and the drug is contraindicated in cases of severe hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Mechanism of Action Studies

Research has explored the compound's characteristics and the investigation of its effect on the symptoms of type 2 diabetes. Studies focused on its action as a meglitinide-class agent, which stimulates insulin release from the pancreatic beta cells.

  • Preclinical Findings: Initial in vitro and animal model studies were conducted to understand the compound's characteristics, noting its rapid onset of action.
  • Pharmacokinetic Profile: Clinical trials examined the compound's absorption profile, half-life, and distribution across tissues. It is noted to be rapidly absorbed.

Key Efficacy Trials

Studies have explored the clinical effects of nateglinide monotherapy and in combination with other oral antidiabetic agents.

Phase 3 Trial (The Landmark Study)

A multi-center, randomized, placebo-controlled Phase 3 trial was conducted to evaluate clinical outcome measures, enrolling approximately 1,200 participants with type 2 diabetes.

  • Observed Glycemic Improvement: In primary trials, patients reported improvement in postprandial (after-meal) blood glucose levels. Studies also observed reductions in HbA1c (a long-term measure of glucose control) when compared to placebo.
  • Combination Therapy: The combination of nateglinide and metformin was examined and was associated with reductions in both fasting and postprandial glucose levels.

Safety and Tolerability Data

Safety data was collected throughout all trial phases, including adverse event reporting and laboratory monitoring.

Specific Populations

  • Kidney Impairment: Studies included patients with mild-to-moderate renal impairment to examine the compound's tolerability. The study protocol included assessment of renal clearance.
  • Drug Interactions: Research has explored the concurrent use of nateglinide with certain agents, including warfarin, digoxin, and other antidiabetic medications. The clinical significance of some potential interactions is not yet clear.

Frequently Asked Questions (FAQ)

Common questions about Starlix (FAQ)


Q: How is Starlix different from Metformin?

Starlix (nateglinide) and Metformin belong to different classes of diabetes medications. According to official product information, Starlix is a type of medication called a meglitinide that works by stimulating the pancreas to release insulin, particularly around mealtime. Metformin, on the other hand, belongs to the biguanide class and works primarily by helping your body reduce the amount of glucose (sugar) produced by the liver.


Q: Will Starlix make me feel shaky or dizzy?

The prescribing information notes dizziness as a common side effect. As with any drug that lowers blood sugar, there is a risk of hypoglycemia (low blood sugar), and symptoms of low blood sugar can include shakiness or tremors.


Q: Does Starlix interact with common blood pressure medications?

Yes, the official label notes that certain drugs that affect the sympathetic nervous system, such as some beta-blockers, may enhance the glucose-lowering effect of Starlix. These types of interactions can also potentially mask some of the symptoms of low blood sugar.


Q: Can I take Starlix if I also take a statin for cholesterol?

Official labeling does not typically list a specific required dose change when combining Starlix with statins (cholesterol-lowering drugs). However, Starlix is metabolized by certain enzymes that may also affect the levels of some statins. Concurrent use of these medications requires careful consideration and professional oversight.


Q: Are there any foods I should avoid while on Starlix?

Official warnings specify that consuming alcohol while taking Starlix may significantly increase the risk of low blood sugar (hypoglycemia). Beyond alcohol, no specific food restrictions are listed in the regulatory labeling, though the drug is intended to be used as part of a proper diet plan.


Q: Is Starlix effective for A1C reduction?

Clinical trial data indicate that Starlix was associated with significant reductions in HbA1c (A1C) levels when compared to placebo. This shows its usefulness in the long-term management of blood sugar control.


Q: Can Starlix be taken with insulin?

Starlix is indicated for Type 2 diabetes and has been studied in combination with other oral anti-diabetic agents. The official label does not specifically address co-administration with insulin in detail. However, using Starlix with any other insulin secretagogue (a drug that causes insulin release) increases the risk of hypoglycemia (low blood sugar).


Q: Can Starlix interact with over-the-counter pain relievers like ibuprofen?

Yes, regulatory documents indicate that the blood sugar-lowering effect of Starlix may be enhanced when combined with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), a category which includes common pain relievers like ibuprofen. Monitoring is recommended when these are used together.


Q: Does Starlix cause weight gain?

Clinical trial data showed that patients treated with Starlix experienced statistically significant mean increases in weight when compared to those who took a placebo.


Q: What happens if I miss a dose of Starlix?

The official product information specifically instructs that if a meal is skipped, the scheduled dose of Starlix should also be skipped to help reduce the risk of hypoglycemia. Specific instructions for missing a dose when a meal is eaten are not explicitly detailed in the core regulatory labeling.


Q: What are the long-term side effects of taking Starlix?

The official product information reviews adverse events from trials lasting up to 64 weeks. The most common effects observed in these trials are hypoglycemia, upper respiratory infection, and back pain. Information about side effects beyond this time frame should be discussed with a healthcare professional.


Q: Is Starlix the same as repaglinide?

No, Starlix (nateglinide) is not the same as repaglinide. While both belong to the meglitinide class of medications, official regulatory information specifies that nateglinide is characterized by its very rapid onset and short duration of action compared to other agents in the same class.


Q: Do people on Starlix need to check their blood sugar more often?

Official warnings recommend self-monitoring of blood glucose for all patients on Starlix. Increased frequency of blood glucose monitoring is specifically recommended for patients who may be at a higher risk for low blood sugar or those who have trouble recognizing the symptoms of hypoglycemia.


Q: What are the signs of an allergic reaction to Starlix?

Regulatory reports of hypersensitivity reactions, which are allergic reactions, have been noted in post-marketing experience. These signs can include rash, itching, and urticaria (hives). Any suspected allergic reaction should be reported immediately.


Q: Can Starlix be used by people who don't have Type 2 diabetes?

No, Starlix is strictly indicated only for the management of Type 2 diabetes mellitus in adults. It is officially contraindicated in patients with Type 1 diabetes.


Q: Is there a generic version of Starlix available?

Yes, the active ingredient in Starlix, which is nateglinide, is available as a generic oral tablet. This is common for many branded medications.


Q: Why do doctors tell you to take Starlix right before eating?

The official instructions require Starlix to be taken shortly before meals (1 to 30 minutes). This specific timing is necessary because the drug has a rapid onset and short duration of action, ensuring its blood sugar-lowering effect precisely matches the absorption of glucose from the meal.


Q: Can Starlix affect liver function test results?

Yes, post-marketing reports have included cases of elevated liver enzymes. For this reason, Starlix is officially contraindicated in patients with severe liver impairment, and liver function may be monitored by a healthcare professional.


Q: Are there any serious, but rare, side effects I should know about?

Regulatory documents acknowledge that post-marketing experience has included reports of serious adverse reactions, though they are very rare. These include conditions such as cholestatic hepatitis and Erythema multiforme.


Q: Can women who are pregnant or breastfeeding use Starlix?

Official labeling advises caution in this population. The drug is generally not recommended for use during breastfeeding. For pregnancy, its use is typically advised only if the potential benefit justifies the potential risk to the fetus, as there are no adequate or well-controlled studies.


Q: What happens if Starlix is taken after a meal instead of before?

The medication is designed to be taken before a meal to promote an insulin pulse that coincides with the food. If taken after a meal, the drug may be less effective at controlling the rapid post-meal blood sugar spike, and this shift in timing could potentially increase the risk of delayed hypoglycemia.


Q: Does Starlix affect the digestive system?

Yes, according to regulatory sources, common side effects of Starlix include various gastrointestinal disorders. These may involve symptoms such as diarrhea, abdominal pain, dyspepsia (indigestion), and nausea. Vomiting is also listed as an uncommon side effect.


Q: Are there any dietary restrictions specific to taking Starlix?

The most significant restriction mentioned in official warnings is the consumption of alcohol, as this substantially increases the risk of low blood sugar. The drug must also be used along with a proper diabetic diet and exercise program.


Q: Is it possible to take too much Starlix?

Yes, taking more than the prescribed amount of Starlix could lead to an overdose. The main concern with an overdose is an exaggerated blood sugar-lowering effect, which could lead to hypoglycemia.


Q: Does Starlix require any special monitoring by a doctor?

Yes, official labeling recommends certain checks. Doctors may recommend increased frequency of blood glucose monitoring for patients at risk of low blood sugar. Additionally, because of the potential for elevated liver enzymes, liver function may also be monitored.


Q: Will taking Starlix affect my energy levels?

The official adverse reaction list does not specify changes in energy levels or fatigue as a common side effect. However, if the medication causes hypoglycemia (low blood sugar), symptoms often associated with this condition can include unusual weakness or tiredness.

How should Starlix be stored and disposed of?

Starlix (nateglinide) tablets require specific storage and disposal procedures, as defined by official regulatory labeling, to maintain stability and ensure safety.

Storage and Handling Requirements

Condition Official Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C). Brief storage between 15 C and 30 C is permitted.
Protection Keep away from heat, moisture, and direct light. Keep from freezing. Do not store in the bathroom.
Container Keep in the original container and ensure it is tightly closed; do not use after the expiry date.
Child Safety Must be kept out of the reach and sight of children.

Disposal Instructions

When the medicine is outdated or no longer needed, it must be disposed of properly. Do not throw away via household trash or wastewater. Patients should ask a pharmacist for guidance on the correct method to discard the medicine, ensuring disposal is carried out according to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Starlix found in:

A-Z Index: